Results 281 to 290 of about 44,624 (355)

Detection of residual host cells after bone marrow transplantation using non-isotopic in situ hybridization [PDF]

open access: yes, 1993
Cremer, Thomas   +5 more
core  

What Is Your Diagnosis? Submandibular Mass in a Dog

open access: yes
Veterinary Clinical Pathology, EarlyView.
Whitney K. Chandler   +3 more
wiley   +1 more source

Reticulated Platelets and an Optimal Model for Differentiating Thrombocytopenia Etiologies

open access: yeseJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Objectives This study aimed to investigate the clinical value of reticulated platelets (RtcPLT) percentage derived from an automated hematology analyzer in differentiating thrombocytopenia due to peripheral etiology from decreased bone marrow production (BME). In addition, a secondary objective was to establish specific reference intervals for
Tung Thanh Tran   +5 more
wiley   +1 more source

Platelet‐Rich Fibrin Induces New Bone Formation to Promote Extreme Lateral Interbody Fusion of Spine in Rabbits

open access: yesJOR SPINE, Volume 9, Issue 2, June 2026.
Preparation process of PRF and its promotion of intervertebral fusion. The rabbit lateral fusion model proves that PRF can promote the intervertebral fusion rate of allograft bone. In vitro experiments can be observed that PRF promotes the osteogenic expression of BMSCS.
Weijian Wang   +5 more
wiley   +1 more source

Bone Marrow Aspirate Concentrate Harvest and Delivery With a Neonatal Nasogastric Tube: A Simple Technique in Hip Arthroscopy. [PDF]

open access: yesArthrosc Tech
Salas AP   +6 more
europepmc   +1 more source

Rate of MGUS Progression to Haematological Malignancies: A Systematic Review

open access: yesEuropean Journal of Haematology, Volume 116, Issue 6, Page 889-906, June 2026.
ABSTRACT Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic pre‐cancerous condition that precedes plasma cell dyscrasias, including multiple myeloma (MM). Current clinical guidelines report that MGUS's rate of malignant progression to haematological malignancy (HM) is ~1% per year; however, reported rates have varied widely ...
Stephen James Quinn   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy